Liminatus Pharma, Inc.
LIMN
$0.98
$0.077.39%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.82M | -214.00K | -300.00 | -229.00K | -601.40K |
| Total Depreciation and Amortization | 500.00 | 700.00 | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.10M | -1.27M | -- | -- | -- |
| Change in Net Operating Assets | 119.10K | -7.49M | 300.00 | 88.00K | 395.30K |
| Cash from Operations | -600.60K | -8.98M | 0.00 | -141.00K | -206.10K |
| Capital Expenditure | -13.10K | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | -775.00K | -- | -550.00K | -800.00K |
| Cash from Investing | -13.10K | -775.00K | -- | -550.00K | -800.00K |
| Total Debt Issued | 0.00 | 4.34M | -- | 700.00K | 983.00K |
| Total Debt Repaid | 0.00 | -1.30M | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 10.56M | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -2.56M | -- | -- | 36.00K |
| Cash from Financing | 0.00 | 11.03M | -- | 700.00K | 1.02M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -613.70K | 1.28M | -- | 9.00K | 12.90K |